Quel est le prix pour ReNeuron Group plc (RENE)

Le prix pour ReNeuron Group plc (RENE) est $0.00042815

Quelle est la capitalisation boursière pour ReNeuron Group plc (RENE)

La capitalisation boursière pour ReNeuron Group plc (RENE) est $13.55K

ReNeuron Group plc (RENE) Prix et Capitalisation Boursière

Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.

Prix pour RENE	L’actif B	La capitalisation boursière de B	Résultats
$170,110 $13.55K	NVDA	$5.383T	+39,731,415,695.48%
$139,776 $13.55K	AAPL	$4.423T	+32,646,453,559.22%
$131,465 $13.55K	GOOG	$4.160T	+30,705,244,029.79%
$115,758 $13.55K	MSFT	$3.663T	+27,036,820,392.59%
$91,360.64 $13.55K	AMZN	$2.891T	+21,338,462,301.30%

Prix pour RENE

L’actif B

La capitalisation boursière de B

Résultats

$170,110 $13.55K